Physician profile
Tenzing Phanthok
NPI 1659765287
$4,373.11
in general payments reported to CMS, 2019-2025
27 companies · $2,106 in 2025
The $2,106 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $60.90 · 2022: $121 · 2023: $790 · 2024: $1,170 · 2025: $2,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537 · Travel and Lodging: $1,440 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.04 |
| Travel and Lodging | $1,439.55 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,190.00 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $265.25 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $236.50 | 2023 | |
| Genzyme Corporation | $225.00 | 2024-2025 | |
| Insmed, INC. | $174.05 | 2021-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $150.09 | 2024-2025 | Winrevair |
| United Therapeutics Corporation | $149.75 | 2019-2023 | Orenitram, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $109.80 | 2023-2025 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.29 | 2024-2025 | Ofev, Jascayd |
| Viatris Specialty LLC | $89.57 | 2025 | Yupelri |
| Verona Pharma, INC. | $72.19 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $66.09 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $62.15 | 2023-2025 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $55.81 | 2022-2023 | |
| Mylan Specialty L.P. | $55.12 | 2023-2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $52.30 | 2024-2025 | Opsumit, Opsynvi, Uptravi |
| Amgen INC. | $46.44 | 2024-2025 | Tezspire |
| Grifols USA, LLC | $46.37 | 2025 | Prolastin-C Liquid |
| Getinge USA Sales, LLC | $37.35 | 2024 | Cardiohelp |
| Lilly USA, LLC | $34.88 | 2025 | Zepbound |
| Abbvie INC. | $33.19 | 2023-2025 | |
| Axsome Therapeutics, INC. | $24.75 | 2025 | Sunosi |
| Vifor Pharma, INC. | $24.04 | 2025 | Zemaira |
| Baxter Healthcare | $22.41 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Shionogi INC | $19.73 | 2023 | Fetroja |
| Harmony Biosciences LLC | $19.70 | 2025 | |
| Pfizer INC. | $15.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tenzing Phanthok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.